Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitaliza...
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck...